Kestrel

Ru-106 Eye Applicators

NHS Greater Glasgow and Clyde · published Thu 10 Sep 2026

In plain English

Reading the notice and writing a summary. This takes a few seconds the first time.

The documents are on Public Contracts Scotland, where the bid is sent too. It's free to register there.

The notice as published

NHS Greater Glasgow and Clyde intends to purchase Ru-106 Eye Applicators from Eckert & Ziegler for specialist ocular brachytherapy treatments delivered within NHS Scotland. The purchase includes the supply of radioactive Ru-106 ophthalmic applicators and associated technical support services as required by the clinical service. Ru-106 eye applicators are ophthalmic brachytherapy plaques used primarily for treating uveal melanoma, retinoblastoma, and other ocular tumors. They consist of a thin film of Ru-106 beta-emitting isotope, encapsulated in pure silver sheets, with a total thickness of only 1 mm, making them easy to handle and position on the eye surface. The beta radiation has a limited range, allowing high doses to tumors up to 5 mm in thickness while sparing sensitive structures like the optic disc and fovea. Additional information: Approximately six (6) Ru-106 Eye Applicators required to be purchased and returned per year, this contract will cover a 36 month period